Internal Medicine

Individuals at 15 years old with depression experience struggles with both sleep patterns and sleep quality.

Crysvita received approval from the FDA for treatment of TIO in patients aged 2 years and older.

ADHD symptoms are highly comorbid with insomnia, restless leg syndrome, and snoring.

Antipsychotics commonly cause a number of side effects including weight gain and long-term cardiovascular disease.

Cardiovascular events and death increased by 20% in people with 4 or more depressive symptoms compared to individuals without depressive symptoms.

Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.

A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.

During the induction period, patients in the treatment group had higher incidences of infections and serious infectious compared to placebo.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.

Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.

Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.

The intervention model can be used to help manage a variety of chronic diseases.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.

A dermatologist and clinical associate professor of dermatology discusses implementing telehealth in dermatology practices.

Lower treatment odds for women were also observed in a set of 7 studies that had data on the subgroup of patients eligible for IV rtPA treatment.

The drug reduces the time to improvement of flu symptoms in patients having at least 1 high-risk factor.

Time of cannabis use can predict larger decreases in intrusions and irritability in individuals suffering from PTSD.